Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-11-06 07:00 |
NOUVEAU NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 1ER NOVEMBRE 2…
|
French | 113.5 KB | ||
| 2019-10-29 10:27 |
Franchissement de seuils
|
French | 196.7 KB | ||
| 2019-10-18 17:00 |
Innate Pharma annonce l’exercice intégral de l’option de surallocation accordée…
|
French | 18.7 KB | ||
| 2019-10-18 16:00 |
Innate Pharma annonce l’exercice intégral de l’option de surallocation accordée…
|
French | 110.2 KB | ||
| 2019-10-17 09:30 |
Innate Pharma annonce la suspension du cours de ses actions ordinaires sur Euro…
|
French | 12.2 KB | ||
| 2019-10-17 08:30 |
Innate Pharma annonce la suspension du cours de ses actions ordinaires sur Euro…
|
French | 68.6 KB | ||
| 2019-10-17 08:00 |
Innate Pharma annonce la fixation du prix de son introduction en bourse sur le …
|
French | 52.5 KB | ||
| 2019-10-17 07:00 |
Innate Pharma annonce la fixation du prix de son introduction en bourse sur le …
|
English | 160.7 KB | ||
| 2019-10-07 08:00 |
Innate Pharma annonce le lancement de son introduction en bourse sur le Nasdaq …
|
French | 32.0 KB | ||
| 2019-10-03 08:00 |
Innate Pharma announces publication of a review article in Nature
|
English | 16.8 KB | ||
| 2019-10-03 08:00 |
Innate Pharma annonce la publication d’un article de synthèse dans Nature
|
French | 17.7 KB | ||
| 2019-10-01 08:00 |
INNATE PHARMA PRÉSENTE DES RESULTATS CLINIQUES PRELIMINAIRES SUR IPH5401 ET MON…
|
English | 23.5 KB | ||
| 2019-10-01 08:00 |
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ES…
|
English | 20.1 KB | ||
| 2019-09-26 08:00 |
Monalizumab to advance to Phase III in head and neck cancer
|
English | 15.5 KB | ||
| 2019-09-26 08:00 |
Monalizumab va entrer en Phase III dans le cancer de la tête et du cou
|
French | 16.7 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
